Functionalisation of Virus-Like Particles Enhances Antitumour Immune Responses

Figure 1

gp100 RHDV VLP design and expression. Each gp100 RHDV VLP was expressed in Sf21 cells and purified for analysis and applications in vaccination. (a) Diagram outlining the structure and linker position for each gp100 VLP. (b) SDS-PAGE for RHDV VLP with one (gp100.1, 1LN, 1LC and 1LNC), two (gp100.2L), and three (gp100.3L) gp100 epitopes compared to unmodified VP60. (c) Electron microscopy to confirm particle formation for gp100.1, 2L, and 3L.

(a)

(b)

(c)